Why imatinib remains an exception of cancer research

Area of Science:

• Oncology
• Molecular Biology
• Cancer Evolution

Background:

• The success of imatinib in treating chronic myeloid leukemia (CML) established targeted therapy as a cornerstone of cancer treatment.
• However, similar molecular targeting successes have not been replicated in most solid tumors, creating a significant gap in effective therapies.
• Prostate cancer, despite sharing a fusion gene with CML, serves as a model for understanding this disparity in solid tumors.

Purpose of the Study:

• To investigate the fundamental differences between chronic phase chronic myeloid leukemia (CML-CP) and solid tumors like prostate cancer.
• To elucidate the evolutionary patterns that explain why imatinib's success in CML-CP is not mirrored in solid tumors.
• To propose a shift in cancer research focus from gene-centric to genome-based theories for understanding solid tumor evolution.

Main Methods:

• Comparative analysis of evolutionary features between CML-CP and solid tumors (prostate cancer).
• Examination of key characteristics including cell population dynamics, oncogene penetrance, and genetic progression patterns.
• Review of the effectiveness of molecular targeting in different cancer contexts.

Main Results:

• CML-CP is characterized by a large, unconstrained cell population, a dominant oncogene sweep, ordered clonal evolution, and effective targeting in its chronic phase.
• Solid tumors exhibit highly dynamic and stochastic evolutionary patterns, contrasting with the stepwise model of CML-CP.
• These distinct evolutionary dynamics explain the limited success of targeted therapies like imatinib in most solid tumors.

Conclusions:

• The unique evolutionary trajectory of CML-CP, unlike the stochastic evolution of solid tumors, underpins imatinib's exceptional efficacy.
• Understanding these differences is crucial for developing effective targeted therapies for solid tumors.
• A genome-based theoretical framework is essential for advancing our comprehension of solid tumor evolutionary dynamics and therapeutic strategies.